Discover a new way to find and share stories you'll love… Learn about Reading Desk

All Blogs / Industries / Medical / Pharmaceutical / New


Chemistry on Android

A reader sends along an organic chemistry mechanisms game that he's released on Google Play. I don't have an android device, so I haven't tried it out myself, but those of you who teaching organic (or looking for ways to teach it), have a look and send along some feedback. Show More Summary

Science And Dramatic Art: Any Intersections?

Someone asked me this the other day, and I've never had a good answer for it. Has there ever been a realistic, compelling depiction of of what it's like to do scientific research in any movie, TV show, or play? My own answer is thatShow More Summary

Nivolumab Racks Up Another Success

I'm always happy to highlight impressive clinical data, and this is impressive. Bristol-Myers Squibb's nivolumab (which has been doing very well in clinical trials so far) apparently has very significant effects in refractory squamous cell lung cancer as well. Show More Summary

Down With the Western Blot?

A reader sends along a thought that touches on a lot of the publication scandals that have happened in molecular biology over the years. A very common feature of these is manipulation of Western blots (see that graphic the other dayShow More Summary

News Roundup, October 2014: Walgreens, Cardinal Health, Generics, Marley Drugs, and Roger Daltrey

Eeek! Time for my Halloween-themed roundup of Drug Channels news stories. In this issue: Icky: Walgreen’s ex-CFO alleges defamation Spooky: Generic inflation is changing benefit design It’s alive! An independent pharmacy thrives with...Show More Summary

Google's Nanoparticle Diagnostic Ideas

Google's "Google X" division, the part that works on odd high-risk high-reward projects, is apparently interested in diagnostic nanoparticles. That Wired article is pretty short on specifics, but the company's Andrew Conrad revealed a few details in a talk yesterday. Show More Summary

Aileron Heads Toward the Clinic

Aileron, the stapled-peptide company, has had its ups and downs over the past few years. They went through the typical cut-back-hard phase not too long ago, but have been rounding up more money to try out their p53-targeted idea (blogged on here). I'm glad to hear it. Show More Summary

Viehbacher Out at Sanofi

The talk of Chris Viehbacher being in trouble with Sanofi's board of directors was accurate: he's been dismissed. It was a unanimous vote, and the chairman cited a lack of trust and a "solitary management style" as factors. (This after...Show More Summary

Sovaldi: The Legendary Blockbuster

Yesterday, Gilead Sciences reported another blockbuster quarter for Sovaldi sales. (Read the press release.) But just how good was Sovaldi’s launch? Mark Schoenebaum of ISI Group compared hepatis C treatment Sovaldi’s launch to the launch of such other legendary drugs as Avastin, Gleevec, Revlimid, and more. Show More Summary

Rumblings About AstraZeneca and Antibiotics

Well, let's get the rest of today's bad news out there. There are persistent reports that AstraZeneca is going to be getting rid of the rest of its antibiotics research. David Shlaes' blog is the source of this one, and he may well have some information from people who know. Show More Summary

Amgen Cuts Harder

Not good news. Amgen has announced that it's not just cutting 12 to 15% of its employees - it's going to cut 20% of them. So that means over a thousand new layoffs, on top of the ones that have already been put in the hopper. No details...Show More Summary

An Open-Source Cancer Pitch, Deconstructed

I'm confused. Read this and see if you end up the same way. TechCrunch has the story of Isaac Yonemoto, who's crowdsourcing a project around a potential oncology compound. It's a derivative of sibiromycin, a compound I hadn't come across, but it seems that it was first studied in Russia, and then at Maryland. Show More Summary

Fazlul Sarkar Subpoenas PubPeer

Last month I mentioned that a professor at Wayne State, Fazlul Sarkar, was thinking of suing the PubPeer site or its commenters, after a host of negative comments on his papers disrupted his move to the University of Mississippi. Well,...Show More Summary

Sanofi - Trouble At the Top?

There are reports that Sanofi's CEO, Chris Viehbacher, is in trouble with the company's board of directors. The reasons are various, ranging from his move to Boston, through the state of the company's oncology portfolio, all the way to his outspokenness, which is not very French. Show More Summary

Sarepta's Duchenne Therapy Is A Lot Further Away

I wrote here about Sarepta, a small company having plenty of difficulty getting a therapy for Duchenne muscular dystrophy through the FDA. At that point, the problem was the accelerated-approval pathway, but things have now gotten aShow More Summary

Farzul Sarkar Subpoenas PubPeer

Last month I mentioned that a professor at Wayne State, Fazlul Sarkar, was thinking of suing the PubPeer site or its commenters, after a host of negative comments on his papers disrupted his move to the University of Mississippi. Well,...Show More Summary

PBMI's 20th Annual Drug Benefit Conference

Here's a cool conference: The Pharmacy Benefit Management Institute (PBMI) will host its 20th Annual Drug Benefit Conference at the San Antonio Marriott Rivercenter hotel in San Antonio, TX, on March 2-4, 2015. Many attendees will be from employers, health plans, and unions, so you’ll learn the payers' perspectives on pharmacy benefits. Show More Summary

Ben Goldacre: Pharma industry has destroyed its own reputation

Ben Goldacre [Scott Hurst/Flickr] EXCLUSIVE: The great tragedy for the pharmaceutical industry is that it keeps denying that it lobbies against transparency in clinical trials, says Ben Goldacre. Ben Goldacre is a British physician, academic and author of the best-selling books Bad Science and Bad Pharma. Show More Summary

Copyright © 2011 Regator, LLC